

October 29, 2026

The General Manager
Pakistan Stock Exchange Ltd
Stock Exchange Building
Stock Exchange Road
Karachi.

Subject: Financial results for the quarter ended September 30, 2026.

Dear Sir,

We have to inform you that the Board of Directors of IBL HealthCare Limited in their meeting held on Wednesday, October 28, 2026 at 03:30 p.m. at Karachi, has recommended the following;

- | | | | |
|-------|----------------------------------|---|------|
| (i) | Cash Dividend | : | Nil |
| (ii) | Bonus Shares | : | Nil |
| (iii) | Right Shares | : | Nil |
| (iv) | Any other | : | None |
| | Entitlement/
Corporate Action | | |
| (v) | Any other price | : | None |
| | Sensitive information | | |

The financial results of the company are attached herewith.

The Quarter report of the company for the quarter ended September 30, 2026, will be transmitted through PUCARS within specified time.

Yours faithfully,
for IBL HealthCare Limited



Hussain Murtaza
Company Secretary

IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT SEPTEMBER 30, 2026

	Note	Un-audited September 30, 2026	Audited June 30, 2026
----- (Rupees in '000) -----			
ASSETS			
Non-current assets			
Property and Equipment	5	20,010	20,815
Right-of-use asset		15,776	16,950
Investment properties		587,374	587,374
Intangible assets		718	861
Deferred taxation - net		13,618	13,618
		637,496	639,618
Current assets			
Inventories		706,575	884,186
Trade and other receivables	6	1,696,024	1,532,259
Advances, deposits and prepayments	7	234,886	179,709
Short-term investments	8	253,834	-
Refunds due from government - sales tax		3,715	12,619
Taxation - payments less provision		62,816	58,597
Cash and bank balances	9	191,361	727,182
		3,149,211	3,394,552
Total assets		3,786,707	4,034,170
EQUITY AND LIABILITIES			
Share capital and reserves			
Share Capital			
Issued, subscribed & paid up capital	10	985,260	985,260
Capital reserve			
Share premium		119,600	119,600
Revenue reserve			
Unappropriated profit		1,502,642	1,438,592
		2,607,502	2,543,452
Liabilities			
Non-current liabilities			
Lease liability		15,046	16,080
		15,046	16,080
Current liabilities			
Trade and other payables	11	1,112,792	1,419,247
Contract liabilities		26,255	23,823
Short term borrowings	12	0.00	6,728
Current portion of lease liability		4,051	3,779
Unclaimed dividend		7,042	7,042
Unpaid dividend	13	14,019	14,019
		1,164,159	1,474,638
Contingencies and commitments	14		
Total equity and liabilities		3,786,707	4,034,170

The annexed notes 1 to 22 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer



IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME (Un-audited)
FOR THE PERIOD ENDED SEPTEMBER 30, 2026

	Note	September 30, 2026	September 30, 2025
		----- (Rs. in '000) -----	
Revenue from contract with customers	15	1,121,185	1,120,918
Cost of Sales		(729,339)	(720,829)
Gross Profit		391,846	400,089
Other income / (loss)	16	7,622	2,184
Marketing and distribution expenses		(238,643)	(230,133)
Administrative and general expenses		(68,173)	(39,818)
Profit from operations		92,652	132,322
Finance cost	17	(1,000)	(9,195)
Profit before levies and income tax		91,652	123,127
Levies - minimum tax	18	(1,099)	(8,498)
Profit before taxation		90,553	114,629
Income tax expense	19	(26,503)	(44,941)
Profit after taxation		64,050	69,688
Other comprehensive income		-	-
Total comprehensive income		64,050	69,688
			(Re-stated)
Earnings per share - basic and diluted		0.65	0.71

The annexed notes 1 to 22 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer



IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (Un-audited)
FOR THE PERIOD ENDED SEPTEMBER 30, 2026

	Issued, subscribed & paid up capital	Reserve for issue of bonus shares	Share Premium	Unappropriated profit	Total share holders' equity
	(Rupees in '000)				
Balance as at July 01, 2025	856,748	-	119,600	1,346,702	2,323,050
Transactions with owners					
Total comprehensive income for the period ended September 30, 2025	-	-	-	69,688	69,688
Balance as at September 30, 2025	856,748	-	119,600	1,416,390	2,392,738
Balance as at July 01, 2026	985,260	-	119,600	1,438,592	2,543,452
Transactions with owners					
Total comprehensive income for the period ended September 30, 2026	-	-	-	64,050	64,050
Balance as at September 30, 2026	985,260	-	119,600	1,502,642	2,607,502

The annexed notes 1 to 22 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer




IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS (Un-audited)
FOR THE PERIOD ENDED SEPTEMBER 30, 2026

	Note	September 30, 2026 ------(Rupees in '000)-----	September 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before levies and income tax		91,652	123,127
Adjustments for non-cash items:			
Unrealized gain on remeasurement of short-term investments		(3,652)	-
Depreciation of furniture and equipment		1,500	1,340
Depreciation of right-of-use asset		1,175	621
Amortization of intangible assets		143	189
Finance cost		1,000	9,195
		<u>91,818</u>	<u>134,472</u>
Decrease/(Increase) in working capital			
Inventories		177,611	110,772
Trade and other receivables		(163,765)	(512,350)
Advances, deposits and prepayments		(55,177)	(26,406)
Refunds due from government - sales tax		8,904	32,908
Trade and other payables		(296,780)	(168,847)
Contract liabilities		2,432	(15,642)
		<u>(326,775)</u>	<u>(579,565)</u>
Cash generated from operations		<u>(234,957)</u>	<u>(445,093)</u>
Income tax paid		(31,820)	(21,632)
Finance cost paid		(10,675)	(12,533)
Net cash (used) in /generated from operating activities		<u>(277,452)</u>	<u>(479,258)</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments for acquisition of furniture and equipment		(696)	(2,722)
Net cash (used) in investing activities		<u>(696)</u>	<u>(2,722)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		0	(15)
Short-term loan obtained		81,848	1,338,538
Short-term loan repaid		(88,578)	(1,040,211)
Payments against lease liability		(762)	(1,239)
Net cash (used) in financing activities		<u>(7,492)</u>	<u>297,073</u>
Net (decrease) in cash and cash equivalents		<u>(285,640)</u>	<u>(184,907)</u>
Cash and cash equivalents at the beginning of the period		727,182	208,938
Cash and cash equivalents at the end of the period	20	<u>441,542</u>	<u>24,031</u>

The annexed notes 1 to 23 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

